<DOC>
	<DOCNO>NCT00777140</DOCNO>
	<brief_summary>Iron overload associate great brain injury ischemia/reperfusion experimental stroke model ischemic stroke patient , especially treat thrombolytic treatment . Deferoxamine administration , iron chelator , offer neuroprotective action ischemia/reperfusion animal model . Primary objective : To evaluate security tolerability deferoxamine endovenous treatment acute ischemic stroke patient treat iv . tPA . Secondary objective : To study pharmacokinetics deferoxamine give endovenous bolus ( 10 mg/Kg ) follow 72-hour continuous intravenous infusion ( 20 , 40 60 mg/Kg ) . To evaluate deferoxamine effect clinical outcome , infarct volume hemorrhagic transformation brain edema development . Methodology : Double-blind , randomize , placebo control , dose-finding phase II clinical trial . Study stage : 1st : bolus+20 mg/Kg/day v . Placebo ( n=15:5 ) ; 2nd : bolus+40 mg/Kg/day v . Placebo ( n=15:5 ) ; 3rd : bolus+60 mg/Kg/day v placebo ( n=15:5 ) . These dos increase accord security result previous stage . Patients continuously monitor stroke unit . Laboratory parameter measure baseline , 24h , 72h 30 day evaluate adverse event related drug . Serum deferoxamine feroxamine concentration measure along time injection subgroup patient pharmacokinetics study . CT scan perform 24-36h ass hemorrhagic transformation brain edema . The NIH Stroke Scale evaluate hospitalization , Rankin score discharge 3 month . If deferoxamine demonstrate secure well tolerate treatment acute stroke patient , may new therapy option lower brain injury ischemia reperfusion .</brief_summary>
	<brief_title>Thrombolysis Deferoxamine Middle Cerebral Artery Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Infarction , Middle Cerebral Artery</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Age 1880 year old Acute Ischemic Stroke middle cerebral artery territory Treatment iv tPA first 3 hour symptom onset Modified Rankin Scale equal 2 Infectious , inflammatory , neoplastic hematologic disease Anemia ( Hto &lt; 34 % Hb &lt; 10g/dl ) Previous renal failure Previous treatment oral iron supplement Minor stroke ( NIHSS less 4 ) , lacunar posterior territory Alcohol consumption ( 40mg/Kg ) Pregnancy Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Thrombolytic treatment</keyword>
	<keyword>Middle cerebral artery occlusion</keyword>
	<keyword>Deferoxamine</keyword>
	<keyword>Iron chelator</keyword>
	<keyword>Acute Ischemic Stroke treat Intravenous Thrombolytic</keyword>
</DOC>